Rituximab in the management of retroperitoneal fibrosis: A  single tertiary rheumatology care center experience

ConclusionOur study shows that rituximab may be a favorable treatment option for glucocorticoid-refractory RPF patients with high disease activity on PET-CT scans.

Source: International Journal of Rheumatic Diseases - September 4, 2023 Category: Rheumatology Authors: Mert Oztas, Izzet Altun, Ali Yagiz Ayla, Emir Cerme, Cetin Demirdag, Sertac Asa, Kerim Sonmezoglu, Serdal Ugurlu Tags: ORIGINAL ARTICLE Source Type: research